Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 2/20 | 0.62 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.62 |
| ▸ | PRMT8 | Q9NR22 | 2/20 | 0.62 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18289222 | 0.89 | CARM1 (0.53) | CARM1PRMT6PRMT8PRMT1HTT | |
| SCHEMBL13919787 | 0.84 | PRMT6 (0.42) | CARM1PRMT6PRMT8PRMT1HRH3 | |
| SCHEMBL13659629 | 0.82 | CARM1 (0.41) | CARM1PRMT6PRMT8PRMT1ACHE | |
| SCHEMBL18774759 | 0.82 | PRMT6 (0.41) | CARM1PRMT6PRMT8PRMT1HTT | |
| SCHEMBL4569287 | 0.81 | CARM1 (0.58) | CARM1PRMT6PRMT8PRMT1HRH3 | |
| SCHEMBL13787914 | 0.81 | CARM1 (0.52) | CARM1PRMT6PRMT8PRMT1POLB | |
| SCHEMBL20003977 | 0.79 | KDM4E (0.46) | CARM1PRMT6PRMT8PRMT1HRH3 | |
| SCHEMBL21214401 | 0.79 | KDM4E (0.46) | CARM1PRMT6PRMT8PRMT1HRH3 | |
| SCHEMBL19226319 | 0.79 | KDM4E (0.46) | CARM1PRMT6PRMT8PRMT1HRH3 | |
| SCHEMBL5226705 | 0.79 | CARM1 (0.56) | CARM1PRMT6PRMT8POLBHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9873709-B2 | Triazolopyridine compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2018-01-23 | — | — | US | disclosed |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-7498405-B2 | Halogen-substituted thienyl compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | CARM1 3887/4885PRMT6 1456/4885PRMT8 1766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.